This interview with a US-based KOL provides insights into current prescribing habits on- and off-label in WHO groups 1–5, key marketed brands and their placement in the treatment algorithm, and expectations for late-phase pipeline therapies for pulmonary hypertension. Key assets highlighted include sotatercept, Tyvaso, Adempas, Orenitram, Remodulin, Letairis, Adcirca, Opsumit, Opsynvi, Yutrepia, Uptravi, ralinepag, KER-012, GB002, INS-1009, AV-101, and AER-901.

This interview was conducted on 10 August 2023.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.